Silence Therapeutics (NASDAQ:SLN) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research note released on Thursday, Benzinga reports. HC Wainwright currently has a $75.00 target price on the stock.

A number of other brokerages have also weighed in on SLN. Morgan Stanley reaffirmed an overweight rating and issued a $45.00 price target on shares of Silence Therapeutics in a research note on Monday, April 22nd. Chardan Capital reissued a buy rating and issued a $42.00 price objective on shares of Silence Therapeutics in a research report on Friday, May 17th.

Silence Therapeutics Stock Performance

SLN opened at $19.00 on Thursday. The stock has a market capitalization of $568.67 million, a PE ratio of -16.38 and a beta of 1.34. Silence Therapeutics has a 1-year low of $4.84 and a 1-year high of $27.72. The firm has a 50-day moving average price of $21.15 and a two-hundred day moving average price of $21.03.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Thursday, May 16th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.18. The company had revenue of $15.73 million during the quarter, compared to analysts’ expectations of $4.53 million. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. On average, research analysts predict that Silence Therapeutics will post -1.52 EPS for the current year.

Hedge Funds Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Silence Therapeutics during the fourth quarter worth about $110,000. Vivo Capital LLC bought a new position in Silence Therapeutics in the 4th quarter valued at approximately $8,862,000. Parkman Healthcare Partners LLC increased its position in Silence Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares during the period. Redmile Group LLC acquired a new stake in Silence Therapeutics during the 1st quarter valued at approximately $43,798,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Silence Therapeutics during the 1st quarter worth approximately $13,575,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.